Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 19M | 19M | 24M | 35M | 44M |
| Gross Profit | 11M | 11M | 13M | 21M | 29M |
| Operating Income | -2M | -3M | -9M | -17M | -20M |
| EBITDA | -367K | -1M | -6M | -14M | -17M |
| Net Income | -2M | -4M | -23M | -70M | -23M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.72
+4.80% today
1Y Change
-19.13%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
cbdMD, Inc. (YCBD) is a Healthcare stock with a market cap of $10.00M and listed on AMEX. The stock last traded around $0.72 and down 19.1% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of -1.5%, EPS growth of +39.1%, a dividend yield of 0.0%. What stands out right now is revenue -1.5%, EPS +39.1%, free cash flow -154.6% with operating margin -12.4% and ROIC -0.4%. Valuation is more restrained than many high-expectation growth names at price/sales 0.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines YCBD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
YCBD
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
YCBD Max Drawdown
-71.19%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for YCBD and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$44.5M
+25.6% YoY
FY Net Income
-$23.4M
+66.6% YoY
Free Cash Flow
-$16.4M
-5.0% YoY
Revenue Growth
-1.5%
EPS Growth
+39.1%
Gross Margin
55.0%
Net Margin
-12.3%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 19M | 19M | 24M | 35M | 44M |
| Gross Profit | 11M | 11M | 13M | 21M | 29M |
| Operating Income | -2M | -3M | -9M | -17M | -20M |
| EBITDA | -367K | -1M | -6M | -14M | -17M |
| Net Income | -2M | -4M | -23M | -70M | -23M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2M | 2M | 2M | 7M | 26M |
| Total Assets | 10M | 11M | 16M | 41M | 125M |
| Total Liabilities | 3M | 9M | 7M | 9M | 22M |
| Shareholder Equity | 7M | 2M | 9M | 31M | 103M |
| Total Debt | 778M | 1M | 4M | 5M | 6M |
| Net Debt | 776M | -1M | 2M | -2M | -20M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
14M
+5.8% YoY
Capital Expenditures
2M
-240.1% YoY
Free Cash Flow
16M
-5.0% YoY
Key ratios
Gross Margin
55.0%
Operating Margin
-12.4%
Net Margin
-12.3%
ROE
-40.7%
Debt / Equity
65.83x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.